Philippe Menu - 18 Mar 2026 Form 3 Insider Report for SOPHiA GENETICS SA (SOPH)

Reporting relationship: Chief Medical Officer
Issuer ticker: SOPH
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 09:45:57 UTC
Next SEC filing: 20 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu

Key filing fact

Philippe Menu filed Form 3 for SOPHiA GENETICS SA (SOPH) on 18 Mar 2026.

Key facts

This page summarizes Philippe Menu's Form 3 filing for SOPHiA GENETICS SA (SOPH).
0 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 09:45.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002014308 Primary reporting owner

Menu Philippe

Relationship: Chief Medical Officer
Address: C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND
Signature: /s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SOPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 174,224
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SOPH holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 30,000
Exercise price: $4.15
Footnotes: F2

SOPH holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 52,000
Exercise price: $6.31
Footnotes: F2

SOPH holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 75,472
Exercise price: $18.00
Footnotes: F2

SOPH holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 185,874
Exercise price: $4.72
Footnotes: F3

SOPH holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 251,524
Exercise price: $4.96
Footnotes: F4

SOPH holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 187,500
Exercise price: $3.29
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 2,704 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 37,833 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 32,027 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

Footnote F2

The share options are fully vested and exercisable.

Footnote F3

The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.

Footnote F4

The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.

Footnote F5

The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

SEC remarks

Exhibit list - Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .